Arch Therapeutics, Inc.
Arch Therapeutics, Inc. (ARTH) Revenue
Annual & quarterly revenue history · segment & region breakdown
ARTH · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsArch Therapeutics, Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 383.80% year-over-year from $0.00B in FY2023.
Revenue trend
2023 – 2011 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2023-09-30 | $0.00B | +$0.00B | +383.80% |
| 2022-09-30 | $0.00B | +$0.00B | +35.34% |
| 2021-09-30 | $0.00B | +$0.00B | — |
| 2020-09-30 | $0.00B | +$0.00B | — |
| 2019-09-30 | $0.00B | +$0.00B | — |
| 2018-09-30 | $0.00B | +$0.00B | — |
| 2017-09-30 | $0.00B | +$0.00B | — |
| 2016-09-30 | $0.00B | +$0.00B | — |
| 2015-09-30 | $0.00B | +$0.00B | — |
| 2014-09-30 | $0.00B | +$0.00B | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Arch Therapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Arch Therapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Arch Therapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
ARTH revenue · 4 questionsARTH's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 383.80% year-over-year from $0.00B in FY2023.
▸ Source: FMP · Arch Therapeutics, Inc. SEC filings · GAAP · Arch Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026